Inhaled Antibiotics

Pediatric Pulmonology

Volumn 37, Issue SUPPL. 26, 2004, Pages 92-94

  Tiddens, Harm ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; AZTREONAM; CEFTAZIDIME; COLISTIN; GENTAMICIN; TOBRAMYCIN; ANTIINFECTIVE AGENT;

AIRWAY OBSTRUCTION; ANTIBIOTIC THERAPY; BRONCHUS OBSTRUCTION; CHILD; CYSTIC FIBROSIS; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRY POWDER; ERADICATION THERAPY; GRAM NEGATIVE INFECTION; HUMAN; LUNG ASPERGILLOSIS; LUNG FUNCTION; LUNG TOXICITY; NEBULIZER; PARTICLE SIZE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SPUTUM CULTURE; ARTICLE; CHRONIC DISEASE; INHALATIONAL DRUG ADMINISTRATION;

ADMINISTRATION, INHALATION; ANTI-BACTERIAL AGENTS; AZTREONAM; CHRONIC DISEASE; CYSTIC FIBROSIS; HUMANS; NEBULIZERS AND VAPORIZERS; PSEUDOMONAS INFECTIONS; TOBRAMYCIN;

EID: 2342421997     PISSN: 87556863     EISSN: None     Source Type: Journal    
DOI: 10.1002/ppul.70065     Document Type: Review

References (22)

1. Levy J, Smith AL, Kenny MA, Ramsey B, and Schoenknecht FD. 1983. Bioactivity of gentamicin in purulent sputum from patients with cystic fibrosis or bronchiectasis: comparison with activity in serum. J Infect Dis 148(6):1069-76.
2. Stead RJ, Hodson ME, and Batten JC. 1987. Inhaled ceftazidime compared with gentamicin and carbenicillin in older patients with cystic fibrosis infected with Pseudomonas aeruginosa. Br J Dis Chest 81(3):272-9.
3. Littlewood JM, Miller MG, Chonheim AT, and Ramsden CH. 1985. Nebulised colomycin for early psudomonas colonisation in cystic fibrosis. Lancet 1:865.
4. Steinkamp G, Tummler B, Gappa M, Albus A, Potel J, Doring G, and von der Hardt H. 1989. Long-term tobramycin aerosol therapy in cystic fibrosis. Pediatr Pulmonol 6(2):91-8.
5. Ramsey BW, Dorkin HL, Eisenberg JD, Gibson RL, Harwood IR, Kravitz RM, Schidlow DV, Wilmott RW, Astley SJ, McBurnie MA, and et al. 1993. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 328(24):1740-6.
6. Cooney GF, Lum BL, Tomaselli M, and Fiel SB. 1994. Absolute bioavailability and absorption characteristics of aerosolized tobramycin in adults with cystic fibrosis. J Clin Pharmacol 34(3):255-9.
7. Ramsey B, Burns J, and Smith A. 1997. Safety and efficacy of tobramycin-solution for inhalation in patients with cystic fibrosis: The results of two fase III placebo controlled clinical trials. Pediatric Pulmonology Suppl 14:137-138.
8. LiPuma JJ. 2001. Microbiological and immunologic considerations with aerosolized drug delivery. Chest 120(3 Suppl):118S-123S.
9. Quittner AL, and Buu A. 2002. Effects of tobramycin solution for inhalation on global ratings of quality of life in patients with cystic fibrosis and Pseudomonas aeruginosa infection. Pediatr Pulmonol 33(4):269-76.
10. Moss RB. 2002. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest 121(1):55-63.
11. Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfeld M, Yunker A, Hamblett N, Accurso F, Dovey M, Hiatt P, Konstan MW, Moss R, Retsch-Bogart G, Wagener J, Waltz D, Wilmott R, Zeitlin PL, and Ramsey B. 2003. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 167(6):841-9.
12. Hofmann T, Otto K, Kirihara J, Flitter W, Mair SJ, Lintz FC, Schuschnig U, Keller M, and Seeman S. 2003. Safety and tolerability study of aztreonam for inhalation (Al) in healthy volunteers. Pediatr Pulmonol Supp 25:A 195.
13. Tiddens HAWM, Phaff SJ, van der Zanden T, and Ruijgrok EJ. 2003. Weekly nebulization of liposomal amphotericine B for the treatment of prednisone dependent ABPA. Pediatr Pulmonol Suppl 25:A 338.
14. Tiddens HAWM, Koopman LP, Lambert RK, Elliott WM, Hop WCJ, van der Mark TW, de Boer WJ, and de Jongste JC. 2000. Cartilaginous airway wall dimensions and airway resistance in cystic fibrosis lungs. European Respiratory Journal 15:735-742.
15. Laube BL, Jashnani R, Dalby RN, and Zeitlin PL. 2000. Targeting aerosol deposition in patients with cystic fibrosis: effects of alterations in particle size and inspiratory flow rate [In Process Citation]. Chest 118(4):1069-76.
16. Janssens HM, Krijgsman AM, Verbraak AFM, Hop WCJ, de Jongste JC, and Tiddens HAWM. 2000. Fine particle size improves lung deposition of inhaled steroids in infants: a study in an upper airway model. Am J Respir Crit Care Med 161 (suppl.):A32.
17. Mallol J, Rattray S, Walker G, Cook D, and Robertson CF. 1996. Aerosol deposition in infants with cystic fibrosis. Pediatr Pulmonol 21(5):276-81.
18. Boe J, Dennis JH, O'Driscoll BR, Bauer TT, Carone M, Dautzenberg B, Diot P, Heslop K, and Lannefors L. 2001. European Respiratory Society Guidelines on the use of nebulizers. Eur Respir J 18(1):228-42.
19. Chua HL, Collis GG, Newbury AM, Chan K, Bower GD, Sly PD, and Le Souef PN. 1994. The influence of age on aerosol deposition in children with cystic fibrosis. European Respiratory Journal 7:2185-2191.
20. Struycken VHJ, Tiddens HAWM, van den Broek ET, Dzoljic-Danilovic G, van der Velden AJCM, and de Jongste JC. 1996. Problemen met gebruik, reiniging en onderhoud van vemevelapparatuur in de thuissituatie. Nederlands Tijdschrift voor Geneeskunde 140:654-658.
21. Rosenfeld M, Emerson J, Astley S, Joy P, Williams-Warren J, Standaert TA, Yim DL, Crist D, Thykkuttathil M, Torrence M, FitzSimmons S, and Ramsey B. 1998. Home nebulizer use among patients with cystic fibrosis. J Pediatr 132(1):125-31.
22. Vassal S, Taamma R, Marty N, Sardet A, d'athis P, Bremont F, Dalphin ML, Plesiat P, Rault G, Thubert J, Dominique S, Lemeland JF, Derelle J, Blech MF, Roussey M, Perrin M, and Sautegeau A. 2000. Microbiologic contamination study of nebulizers after aerosol therapy in patients with cystic fibrosis. Am J Infect Control 28(5):347-51.